[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocardial-bridge-of-coronary-artery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocardial-bridge-of-coronary-artery":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100582017","myocardialbridge-bypass-graft-surgery-efficacy-verification-100582017",false,"NCT06857838","Myocardialbridge Bypass Graft Surgery Efficacy Verification","Inclusion Criteria:\n\n* Patients with myocardialbridge requiring drug therapy or surgical intervention.\n\nExclusion Criteria:\n\n* patients with myocardialbridge not requiring drug therapy or surgical intervention, or unwilling to be enrolled for any reason","ALL","18 Years","80 Years",{"count":19,"type":20},500,"ESTIMATED","INTERVENTIONAL",[23],"NA","Myocardial Bridge Bypass Graft surgery is introduced to relieve the unmedical symptoms of patients with long-segment or deep myocardial bridge, clinical outcomes will be collected to verify the effectiveness of the surgery.",[26,27,28,29,30,31,32,33,34,35],"Myocardial Bridge of Coronary Artery","Myocardial Bridge","Myocardial Bridging","Myocardial Infarction","Myocardial Ischemia","Pectoris, Stable Angina","Sudden Cardiac Death","Bypass Graft Stenosis","Bypass Graft Occlusion","Bypass Graft Thrombosis","RECRUITING","2025-02-26",{"date":39,"type":40},"2025-03-04","ACTUAL",{"date":42,"type":40},"2020-01-01",{"date":44,"type":20},"2040-12-31",{"name":46,"class":47},"Xi'an International Medical Center Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100548733","phase-2-efficacy-of-targeted-medical-therapy-in-angina-and-nonobstructive-coronary-arteries-100548733","NCT06424834","Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries","A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study","MVP-ANOCA","Inclusion Criteria:\n\n* All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study.\n\nSpecific inclusion criteria for randomization:\n\n* Absence of significant epicardial coronary artery disease on angiography\n* Fractional flow reserve \\> 0.80\n\nAnd ≥ 1 of the following:\n\n* Epicardial coronary spasm on acetylcholine testing\n* Microvascular spasm on acetylcholine testing\n* Coronary flow reserve \\\u003C 2.5\n* Index of microcirculatory resistance ≥ 25\n* Myocardial bridge on intravascular ultrasound with dobutamine resting full-cycle ratio ≤ 0.76\n\nExclusion Criteria:\n\n* Acute coronary syndrome less than one week prior to enrolment\n* Cardiomyopathy\n* Contraindications to beta-blockers or calcium channel blockers\n* Baseline systolic blood pressure \\\u003C 95 mmHg\n* Baseline heart rate \\\u003C 55 bpm",{"count":58,"type":20},150,[60,61],"PHASE2","PHASE3","The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing.\n\nParticipants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.",[64,65,66,26],"Angina Pectoris","Microvascular Angina","Vasospastic Angina","2024-11-26",{"date":69,"type":40},"2024-11-27",{"date":71,"type":40},"2024-10-10",{"date":73,"type":20},"2026-12",{"name":75,"class":47},"Stanford University"]